Advanced search
Publication Cover
Leukemia & Lymphoma Volume 62, 2021 - Issue 14
Submit an article Journal homepage
578
Views
5
CrossRef citations to date
0
Altmetric
Original Articles

A phase I/II trial of brentuximab vedotin plus rituximab as frontline therapy for patients with immunosuppression-associated CD30+ and/or EBV + lymphomas

William B. Pearsea Division of Hematology/Oncology, Robert H. Lurie Comprehensive Cancer Center, Feinberg School of Medicine, Northwestern University, Chicago, IL, USACorrespondence[email protected]
ORCID Iconhttps://orcid.org/0000-0003-0580-2419View further author information
ORCID Icon,
Adam M. Petricha Division of Hematology/Oncology, Robert H. Lurie Comprehensive Cancer Center, Feinberg School of Medicine, Northwestern University, Chicago, IL, USAView further author information
,
Leo I. Gordona Division of Hematology/Oncology, Robert H. Lurie Comprehensive Cancer Center, Feinberg School of Medicine, Northwestern University, Chicago, IL, USAView further author information
,
Reem Karmalia Division of Hematology/Oncology, Robert H. Lurie Comprehensive Cancer Center, Feinberg School of Medicine, Northwestern University, Chicago, IL, USAView further author information
,
Jane N. Wintera Division of Hematology/Oncology, Robert H. Lurie Comprehensive Cancer Center, Feinberg School of Medicine, Northwestern University, Chicago, IL, USAView further author information
,
Shuo Maa Division of Hematology/Oncology, Robert H. Lurie Comprehensive Cancer Center, Feinberg School of Medicine, Northwestern University, Chicago, IL, USAView further author information
,
Jason B. Kaplana Division of Hematology/Oncology, Robert H. Lurie Comprehensive Cancer Center, Feinberg School of Medicine, Northwestern University, Chicago, IL, USAORCID Iconhttps://orcid.org/0000-0003-3085-7147View further author information
ORCID Icon,
Amir Behdadb Department of Pathology, Northwestern University Feinberg School of Medicine, Chicago, IL, USAView further author information
,
Andreas Kleinc Department of Hematology/Oncology, Tufts Medical Center, Boston, MA, USAView further author information
,
Borko Jovanovicd Department of Preventive Medicine, Northwestern University, Chicago, IL, USAView further author information
,
Irene Helenowskid Department of Preventive Medicine, Northwestern University, Chicago, IL, USAView further author information
,
Sonali M. Smithe Section of Hematology/Oncology, University of Chicago, Chicago, IL, USAView further author information
,
Andrew M. Evensf Rutgers Cancer Institute of New Jersey, New Brunswick, NJ, USAView further author information
&
Barbara Proa Division of Hematology/Oncology, Robert H. Lurie Comprehensive Cancer Center, Feinberg School of Medicine, Northwestern University, Chicago, IL, USAView further author information
 show all
Pages 3493-3500 | Received 12 Apr 2021, Accepted 12 Jul 2021, Published online: 02 Aug 2021

References

  • Penn I. The role of immunosuppression in lymphoma formation. Springer Semin Immunopathol. 1998;20(3–4):343–355.
  • Swerdlow SH, Campo, E, Harris NL (editors). WHO classification of tumors of haematopoietic and lymphoid tissues. Lyon: IARC Press; 2017. pp. 453–462.
  • Gan YJ, Razzouk BI, Su T, et al. A defective, rearranged Epstein-Barr virus genome in EBER-negative and EBER-positive Hodgkin's disease. Am J Pathol. 2002;160(3):781–786.
  • Meij P, Vervoort MBHJ, Bloemena E, et al. Antibody responses to Epstein-Barr virus-encoded latent membrane protein-1 (LMP1) and expression of LMP1 in juvenile Hodgkin's disease. J Med Virol. 2002;68(3):370–377.
  • Haque T, Chaggar T, Schafers J, et al. Soluble CD30: a serum marker for Epstein-Barr virus-associated lymphoproliferative diseases. J Med Virol. 2011;83(2):311–316.
  • Caussinus E, Meggetto F, Delsol G, et al. Simultaneous occurrence of Epstein-Barr virus associated hodgkin's disease and HHV-8 related multicentric Castleman's disease: a fortuitous event? J Clin Pathol. 2001;54(10):790–791.
  • Evens AM, David KA, Helenowski I, et al. Multicenter analysis of 80 solid organ transplantation recipients with posttransplantation lymphoproliferative disease: outcomes and prognostic factors in the modern era. J Clin Oncol. 2010;28(6):1038–1046.
  • Mamzer-Bruneel MF, Lomé C, Morelon E, et al. Durable remission after aggressive chemotherapy for very late post-kidney transplant lymphoproliferation: a report of 16 cases observed in a single center. J Clin Oncol. 2000;18(21):3622–3632.
  • Elstrom RL, Andreadis C, Aqui NA, et al. Treatment of PTLD with rituximab or chemotherapy. Am J Transplant. 2006;6(3):569–576.
  • Choquet S, Trappe R, Leblond V, et al. CHOP-21 for the treatment of post-transplant lymphoproliferative disorders (PTLD) following solid organ transplantation. Haematologica. 2007;92(2):273–274.
  • Trappe RU, Dierickx D, Zimmermann H, et al. Response to rituximab induction is a predictive marker in B-Cell Post-Transplant lymphoproliferative disorder and allows successful stratification into rituximab or R-CHOP consolidation in an international, prospective, multicenter phase II trial. J Clin Oncol. 2017;35(5):536–543.
  • Johnson LR, Nalesnik MA, Swerdlow SH. Impact of Epstein-Barr virus in monomorphic B-cell posttransplant lymphoproliferative disorders: a histogenetic study. Am J Surg Pathol. 2006;30(12):1604–1612.
  • Fanale MA, Forero-Torres A, Rosenblatt JD, et al. A phase I weekly dosing study of brentuximab vedotin in patients with relapsed/refractory CD30-Positive hematologic malignancies. Clin Cancer Res. 2012;18(1):248–255.
  • Cheson BD, Pfistner B, Juweid ME, and International Harmonization Project on Lymphoma, others. Revised response criteria for malignant lymphoma. J Clin Oncol. 2007;25(5):579–586.
  • Common terminology criteria for adverse events (CTCAE) v. 4.03. US Department of Health and Human Services, National Institutes of Health, National Cancer Institute; 2009. https://searchworks.stanford.edu/view/9100287
  • Fay MP, Brittain EH, Proschan MA. Pointwise confidence intervals for a survival distribution with small samples or heavy censoring. Biostatistics. 2013;14(4):723–726.
  • Trappe RU, Oertel S, Leblond V, and European PTLD Network, others. Sequential treatment with rituximab followed by CHOP chemotherapy in adult B-cell post-transplant lymphoproliferative disorder (PTLD): the prospective international multicentre phase 2 PTLD-1 trial. Lancet Oncol. 2012;13(2):196–206.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.